Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression
© Roth et al; licensee BioMed Central Ltd. 2009
Received: 24 March 2009
Accepted: 7 August 2009
Published: 7 August 2009
It is well recognized that colorectal cancer does not frequently metastasize to bone. The aim of this retrospective study was to establish whether colorectal cancer ever bypasses other organs and metastasizes directly to bone and whether the presence of lung lesions is superior to liver as a better predictor of the likelihood and timing of bone metastasis.
We performed a retrospective analysis on patients with a clinical diagnosis of colon cancer referred for staging using whole-body 18F-FDG PET and CT or PET/CT. We combined PET and CT reports from 252 individuals with information concerning patient history, other imaging modalities, and treatments to analyze disease progression.
No patient had isolated osseous metastasis at the time of diagnosis, and none developed isolated bone metastasis without other organ involvement during our survey period. It took significantly longer for colorectal cancer patients to develop metastasis to the lungs (23.3 months) or to bone (21.2 months) than to the liver (9.8 months). Conclusion: Metastasis only to bone without other organ involvement in colorectal cancer patients is extremely rare, perhaps more rare than we previously thought. Our findings suggest that resistant metastasis to the lungs predicts potential disease progression to bone in the colorectal cancer population better than liver metastasis does.
Colorectal cancer remains the third most common cancer among adult men and women in the United States and the third most common cause of death from cancer [1, 2]. It is well accepted that colorectal cancers metastasize to the liver and lungs more frequently than to bone or other organs . This pattern of involvement has been attributed both to the pattern of blood flow from the colon to the portal system and to molecular signal proteins inherent to the microcosm of each organ system; however; whether one component is more important than the other is still under debate [2–4]. Many studies have focused on characterizing which organ systems are most affected by colorectal cancer metastasis; however, it remains unclear whether there is a specific temporal pattern for metastasis.
If isolated bone metastasis is truly rare in colorectal cancer patients, then clinicians can be very conservative in evaluating a suspected bone lesion without other organ involvement. Because bone metastasis often indicates the terminal phase of colon cancer, clinicians should be more vigilant about possible bone metastasis in colorectal cancer patients with lung metastasis.
The aim of this retrospective study was to establish whether colorectal cancer can bypass other organs and metastasize directly to bone and whether lung metastasis is better than liver metastasis for predicting whether and when bone involvement develops. In addition to determining which other metastasis more effectively predicts impending bone lesions, we determine whether the presence of liver or lung lesions correlates with the increased likelihood and the timing of bone metastasis.
We submitted an application to The University of Texas Medical School at Houston Institutional Review Board, which granted us permission to access patient records for this study from 3 outlying medical facilities. We acquired information retrospectively and gave patient a random numerical code for identification purposes.
We searched the serial imaging reports of all patients referred to these outlying medical facilities from January 2000 to December 2008 with F-18-flurodeoxyglucose (FDG)-PET in correlation with a recent CT or PET/CT and found those with a clinical diagnosis of colon cancer. We analyzed a total of 703 reports from colon cancer patients (an average of 3.04 reports per patient). We attempted to have PET and CT scans for all patients with a diagnosis of colon cancer for staging/restaging or treatment monitoring. Some colon cancer patients never had PET/CT scans because of variable clinical issues or insurance status and these patients were not included in this study. Stage of the patients ranged from stage I to stage IV. We excluded patients if they had a second primary cancer. Thus, we included 252 patients with a primary diagnosis of colorectal cancer in this retrospective study. This group contained 122 female patients (48.4%) and 130 male patients (51.6%).
We included all 252 individuals when we determined organ involvement. However, when calculating the time and sequence of metastatic spread, we found that 21 of the 252 patients had presented solely for initial staging and excluded them from that analysis. The 231 individuals had a known date of initial diagnosis and the time of new metastasis noted in the serial imaging reports during the investigation. Of the 102 patients with organ metastasis, 71 patients received further chemotherapy; 12 patients received combined chemotherapy and surgery; 16 patients received combined chemotherapy and radiation therapy; 2 patients received surgery only; and 5 patients received no therapy. The status of treatment for 5 patients after metastasis was uncertain. Nineteen patients developed new organ metastasis only at the end of our survey periods. Time to development of metastatic disease was defined as time from initial diagnosis to the appearance of metastasis in imaging studies.
To minimize the impact of institutional variability, we included imaging studies only if they had been read originally by 1 of 3 certified nuclear medicine radiologists.
Board-certified nuclear medicine radiologists initially interpreted the imaging studies by using a GE Advanced Workstation for PET/CT cases or MIM vista fusion program (MIM vista Corp) to analyze PET and CT images before we conceived and conducted this study. Another individual subsequently extracted information from the reports to include in this study. Metastases to the liver, lungs, and bone were recorded. Because PET has low sensitivity for detecting brain tumors, we did not assess brain metastases. Disease progression was documented when an imaging report showed involvement of a new organ system. If a metastasis resolved after the patient received therapy, the metastasis was still recorded based on the date on which it was first identified by imaging.
One certified nuclear medicine radiologist reevaluated any inconclusive or contradictory information and confirmed the findings if lesions were visible on subsequent imaging studies or if other imaging modalities confirmed the presence of the lesions. We excluded imaging studies if we could not find a subsequent imaging report to confirm the lesion.
Data were expressed as mean ± SD. We used the Microsoft Excel 2003 to calculate the confidence intervals. We determined the statistical significance of differences by using an unpaired 2-tailed Student t test and considered P values of less than 0.05 to be statistically significant. Because we focused on the temporal pattern of the onset time of organ metastasis, we did not perform Kaplan-Meier survival analysis for this study.
Demographic information of the survey population
Age (mean ± SD)
64.2 year ± 11
Initially staged as I to III
Initially staged as IV
Primary cancer surgery
Adjuvant radiation therapy
Total metastasis to liver, lung, or bone
Organ involvement in the 252 patients comprised metastases to the liver, lung, and bone. There was little difference between male and female patients (data not shown). Overall, 102 of the 252 patients (40%) had organ metastasis.
Colorectal cancer organ metastases in certain criteria
Patient Number (Percentage)
At initial diagnosis
Concurrent with other metastasis
As the first site of organ metastasis
Analysis of metastasis to bone showed 14 of the 252 individuals (5.5%) had bone lesions and no individuals had metastasis only to bone at the time of diagnosis. No patient developed bone metastasis without liver and/or lung metastasis. One individual presented with bone lesions at the time of diagnosis; however, liver metastasis was also present.
Of the 14 patients with lesions to bone, 8 (57%) had both liver and bone involvement, whereas 10 (71%) had lung metastasis. Fifty-three of the 63 patients (84%) with lung lesions remained free of metastasis to bone during follow-up. Similarly, 63 of the 75 patients (84%) with liver metastasis also remained free of metastasis to bone during follow-up.
Average time (months) to organ metastasis in metastatic colon cancer patients
Type of Metastasis
Time ± SD
9.8 ± 14.9
23.3 ± 25.32
21.2 ± 18.52
From liver metastasis to bone metastasis
8.3 ± 13.4
From lung metastasis to bone metastasis
3.3 ± 4.23
Of the 14 patients with metastasis to bone, 2 were still alive, 2 were lost to follow-up, and 8 were dead by the end of this study. The average time from when bone involvement was detected until the patient died was 15.9 months (± 13.2, CI 6.7–25.1), and the average lifespan of patients with bone metastasis after initial diagnosis of colorectal cancer was 42.4 months (± 18.1, CI 29.8–54.9).
Analysis of Involvement in Bone
This study determined that despite individual variance in the degree and order of organ involvement among patients with colorectal cancer, a general temporal pattern does exist. Malignancies never spread primarily to bone. This is a characteristic particular to colorectal cancer as bone metastasis is far more frequent in the other leading cancer types. Although clinicians still cannot agree on the prevalence of breast, lung, and prostate cancers metastasis only to bone is a common occurrence in these cancers . One study even postulated that as many as 70% of patients with stage IV breast cancer have bone involvement . By contrast, cancer typically metastasizes to bone in less than 10% of colorectal cancer patients . This suggests that colon cancer behaves differently with respect to bone metastasis compared with other cancers.
It is also likely that the higher sensitivity and specificity of PET and CT for detecting early metastasis in liver and lung compared with traditional radiography may account for the strong correlation among lesions to the liver, lung, and bone in our study. Possibly, concurrent involvement of other organs did exist but went undetected in the patients who had only bone lesions in the Kanthan et al study . However, confirming whether the complete absence of true isolated bone metastasis is characteristic of colorectal cancer will require a larger study population.
This study sought to identify whether disease progression to the lungs could predict metastasis to bone. Although lung lesions are of particular interest as a forerunner of future bone metastasis as evidenced by the short time span from lung metastasis to bone involvement, the lesions in bone always appear after metastasis to liver, lung, or (in a large percentage) both. As the average 5-year survival rate of colon cancer patients with metastasis to bone continues to be 8.1% , and on average, 67% of those who developed bone involvement during this survey were dead 16 months after detection of bone metastasis, the importance of recognizing disease progression and potential significance of bone metastasis cannot be overemphasized.
The findings in this study regarding colon cancer metastasis to the bone and lungs correlate with results in the current literature. Our findings of lung metastasis in 25% of patients and bone metastasis in 5.5% of patients concur with the results from other studies [2, 8]. As reported in the literature that colorectal cancer metastasizes first to the liver or lungs, which both contain dense capillary beds that can trap tumor cells and seed them into these organs . The environment of a specific organ and its influence on tumor cell adhesion can also contribute to the efficacy of tumor spread, which occurs in colorectal cancer patients most frequently in the liver and lungs [2, 3].
However, the 30% incidence of liver metastasis in our study is much lower than the incidence of liver metastasis in earlier studies, which reported liver involvement in 70–83% of patients [2, 8]. The lower incidence of liver lesions detected in this study may be due to patient selection, because clinicians had resected the primary tumors in most of our patients and were monitoring them to evaluate possible recurrence during the investigation. During the study period, 44% of those who developed liver metastasis remained free of other organ metastasis, and 84% had liver lesions that never progressed to bone.
The percentage of metastatic lung involvement in our study correlates with that reported in the literature. However, unlike people with liver lesions, 78% of people with lung lesions showed concurrent disease involvement in other organs. When combined with the temporal difference between the time from liver metastasis to bone metastasis and the time from lung metastasis to bone metastasis, this finding suggests that lung metastasis indicates refractory, potentially serious disease more precisely than liver metastasis does. Most lung and liver metastases that we observed consisted of multiple lesions. However, solitary lesion occurred more often in the liver than that in the lung.
Although this study attempted to uncover the relationship between the pattern of disease progression and the development of bone metastasis, the resulting subpopulation of patients with metastasis to bone was small, and most had diffuse involvement of multiple organs at the same time point. Thus, further studies with a larger patient population with more frequent imaging studies are necessary to ascertain whether the order of organ involvement has any impact on the development of bone metastasis.
Lymphatic spread and local recurrence were excluded from analysis in this study because most patients had undergone local resection with local lymph node dissection before their staging work-up. Further investigation of the possible relationship between the nodal spread of disease, including local or distant nodal metastasis and metastasis to bone in a different patient population setting, would be interesting. After cancer cells break through the defense barrier of the lymphatic system, especially those lymph nodes outside the portal system, the cancer may metastasize more readily to the lungs and bone. We did not analyze brain metastasis because of the low sensitivity of PET for brain tumor detection and our PET/CT imaging protocol does not include the brain.
A strength of this study is that it included a systematic approach to evaluate disease progression. Using the files of 3 nuclear medicine radiologists facilitated the creation of a large database that spanned institutions, widened demographics, and maintained quality and consistency in the imaging reports.
In addition, unlike most studies that have characterized colorectal cancer metastasis, we used PET and CT, which are newer and more sensitive tools to detect colon cancer metastasis, rather than less precise methods like traditional radiography or bone scintigraphy . Our results are therefore a direct reflection of what diagnosticians can expect to see when staging a colorectal cancer patient using current technology.
A major limitation of this study is the retrospective nature. We obtained the imaging studies during staging and subsequent follow-up by using a combination of PET with correlation of a recent CT and PET/CT. In addition, the imaging modality at each time point varied among patients and we only followed the patients during the imaging periods because of the retrospective nature of the study.
Most of the patients from the 3 outlying medical facilities experienced surgical resection of the primary tumor along with removal of neighboring lymph nodes before they had a detailed staging work-up. This patient population therefore may not be representative of general colorectal patients.
The main implication of this study for clinicians is that if a colorectal cancer patient has no sign of disease involvement in the liver or lungs, evaluation of a suspicious bone lesion should not be aggressive, but should obtain more noninvasive data from other diagnostic modalities or follow-up.
Lung metastasis indicates the potential for cancer to metastasize to bone in the colorectal cancer population better than liver metastasis does.
This manuscript was edited by Tegra Rosera, MA, MS, and Maureen Goode, PhD, ELS, of The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences (supported by National Institutes of Health Clinical and Translational Science Award UL1 RR024148).
- Jemal A, Murray T, Ward E, et al: Cancer Statistics. CA A Cancer Journal for Clinicians. 2005, 55: 10-30. 10.3322/canjclin.55.1.10.View ArticlePubMedGoogle Scholar
- Schluter K, Gassmann P, Enns A, et al: Organ-Specific Metastatic Tumor Cell Adhesion and Extravasation of Colon Carcinoma Cells with Different Metastatic Potential. The American Journal of Pathology. 2006, 169 (Sept): 1064-1073. 10.2353/ajpath.2006.050566.View ArticlePubMedPubMed CentralGoogle Scholar
- Chambers A, Groom A, MacDonald I: Dissemination and Growth of Cancer Cells in Metastatic Sites. Nature. 2002, 2 (August): 563-672.Google Scholar
- Kuo T, Kubota T, Watanabe M, et al: Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci. 1995, 92 (Dec): 12085-12089. 10.1073/pnas.92.26.12085.View ArticlePubMedPubMed CentralGoogle Scholar
- Mundy G: Metastasis to Bone: Causes, Consequences and Theraputic Opportunities. Cancer. 2002, 2 (Aug): 584-593.PubMedGoogle Scholar
- Narisawa S: Understanding Breast Cancer Cell Metastasis to Bone. American Association for Cancer Research. 2001, 42-Google Scholar
- Katoh M, Unakami M, Hara M, Fukuchi S: Bone Metastasis for Colorectal Cancer in Autopsy Cases. Journal of Gastroenterology. 1995, 30: 615-618. 10.1007/BF02367787.View ArticlePubMedGoogle Scholar
- Kathan R, Loewy J, Kanthan S: Skeletal Metastasis in Colorectal Carcinomas: a Saskatchewan Profile. Diseases of Colon and Rectum. 1999, 42 (12): 1592-1597. 10.1007/BF02236213.View ArticleGoogle Scholar
- O'Connell J, Maggard M, Ko C: Colon Cancer Survival Rates with the New American Joint Committee on Cancer Sixth Edition Staging. Journal of the National Cancer Institute. 2004, 96 (19): 1420-1425.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/274/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.